Biogen Inc. (BIIB)
Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)
Biogen Inc. (NASDAQ:BIIB ) TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ET Company Participants Chris Viehbacher - CEO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good morning, and welcome once again to TD Cowen's 45th Annual Healthcare Conference. I'm Phil Nadeau, one of the biotech analysts here at Cowen, and it's my pleasure to moderate a fireside chat with Chris Viehbacher, the CEO of Biogen.
Biogen Stock Is Mutating Into a Value Play
Biogen Inc. NASDAQ: BIIB has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company is trading at historically low valuations at a 12.41 price-earnings (P/E) ratio, which is less than half of the industry average P/E of 29.52.
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, mirroring Aduhelm's failure, and Biogen's pipeline lacks promising products to drive future growth. The multiple sclerosis franchise is in decline, and new drug approvals like Qalsody and Skyclarys have shown minimal revenue impact.
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
On Wednesday, Biogen Inc BIIB reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35.
Biogen Analysts Lower Their Forecasts After Q4 Results
Biogen Inc BIIB reported better-than-expected earnings for its fourth quarter on Wednesday.
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Biogen Inc. (NASDAQ:BIIB ) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Tim Power - Head of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Development Mike McDonnell - CFO Conference Call Participants Salveen Richter - Goldman Sachs Michael Yee - Jefferies Tim Anderson - Bank of America Brian Abrahams - RBC Capital Markets Marc Goodman - Leerink Paul Matteis - Stifel Umer Raffat - Evercore ISI Chris Schott - JPMorgan Evan Seigerman - BMO Capital Markets Phil Nadeau - TD Cowen Operator Good morning. My name is Jennifer and I will be your conference operator today.
Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
Biogen Inc. (BIIB) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.95 per share a year ago.
Biogen's stock hit by soft guidance and a decline in sales of MS drugs
Sales of an Alzheimer's disease treatment were better than expected, but that and a quarterly beat wasn't enough to offset below-consensus EPS outlook.
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth. The biotech company issued a full-year 2025 adjusted earnings outlook of $15.25 to $16.25 per share, which fell short of the $16.34 per share that Wall Street was expecting.
